Rifampicin

證據等級: L5

預測適應症: 10 個

Rifampicin: From Tuberculosis to Conjunctivitis

One-Sentence Summary

Rifampicin is a broad-spectrum antibiotic recognized globally as a cornerstone of tuberculosis treatment, though it is not currently registered in the Philippines. The TxGNN model predicts it may be effective for Conjunctivitis, with 0 registered clinical trials and 20 publications currently supporting this direction. Evidence is predominantly early-era observational and susceptibility studies, placing this indication at L3 — warranting further research before clinical advancement.

Quick Overview

Item	Content
Original Indication	Tuberculosis (established global use; no Philippines registration on record)
Predicted New Indication	Conjunctivitis
TxGNN Prediction Score	99.95%
Evidence Level	L3
Philippines Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Rifampicin exerts its antibacterial effect by binding and inhibiting the β subunit of bacterial DNA-dependent RNA polymerase, halting RNA synthesis. This mechanism confers potent, broad-spectrum bactericidal activity against a wide range of pathogens — including intracellular organisms such as Chlamydia trachomatis, surface-dwelling Staphylococcus aureus, and invasive Neisseria meningitidis — all well-established etiological agents of bacterial conjunctivitis. Notably, rifampicin is, on a weight basis, the most active antibiotic against C. trachomatis (PMID 6635446), the organism responsible for trachoma, the world’s leading infectious cause of blindness.

The connection between rifampicin’s original anti-TB use and conjunctivitis is mechanistically coherent: trachoma is essentially a chronic Chlamydia-driven conjunctivitis, and rifampicin’s anti-chlamydial activity was recognized as early as 1970 (PMID 5411121). A controlled clinical trial conducted in Tunisia in 1975 directly compared topical 1% rifampicin ointment against tetracycline for endemic trachoma, providing early proof-of-concept for ocular use (PMID 1096630). Rifampicin has also appeared in case reports and series as both systemic prophylaxis and definitive treatment for primary meningococcal conjunctivitis, where bacteraemic spread necessitates systemic antibacterial coverage.

A topical ophthalmic formulation can achieve therapeutic concentrations at the corneal and conjunctival surfaces with minimal systemic absorption, yielding a favorable safety profile relative to systemic dosing. However, a clinically important limitation is the rapid emergence of rifampicin resistance with monotherapy — documented in vitro — which argues for its use in combination or restriction to specific indications (e.g., chlamydial trachoma, meningococcal conjunctivitis) where the benefit-resistance trade-off is most favorable.

Clinical Trial Evidence

Currently no related clinical trials registered for rifampicin in conjunctivitis.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
1096630	1975	Clinical Intervention (non-RCT)	Am J Ophthalmology	Controlled trachoma chemotherapy trial in Tunisia (n=234): topical 1% rifampicin ointment vs. 1% tetracycline vs. 5% boric acid, twice daily for 10 weeks; both antibiotic arms showed significant improvement over placebo control
5411121	1970	Preclinical / In vitro	Nature	Rifampicin and rifamycin SV derivatives demonstrated potent anti-trachoma activity, establishing the pharmacological basis for use against ocular Chlamydia infection
6635446	1983	Review	Rev Infect Dis	Rifampin is the most weight-potent antibiotic against C. trachomatis; clinical trials show efficacy comparable to tetracyclines for chlamydial urethral infection and trachoma; resistance emergence is the key concern
5005929	1971	Review	Ann Ophthalmol	Early review summarizing rifampicin’s activity and potential applications across bacterial ocular infections
4250391	1970	Early Clinical Report	Arch Ophtalmol	Early clinical experience with rifampicin use in ophthalmology, documenting initial observations on ocular tolerability and antibacterial efficacy
14686993	2003	Case Report	Clin Microbiol Infect	Primary meningococcal conjunctivitis in a healthy 6-year-old: initial topical polymyxin B/neomycin/gramicidin, followed by systemic rifampin once N. meningitidis confirmed; no ocular or systemic complications
7806886	1994	Case Series	J Infection	Three cases of primary meningococcal conjunctivitis associated with systemic sepsis; management required combined topical and parenteral therapy with rifampicin-based chemoprophylaxis for close contacts
10537781	1999	Review	Curr Opin Ophthalmol	Ocular manifestations of cat-scratch disease including Parinaud’s oculoglandular syndrome; rifampin among agents discussed for treatment of Bartonella-related ocular disease
21191558	2010	Susceptibility Study	Rev Esp Quimioter	Corynebacterium macginleyi strains causing conjunctivitis tested for antibiotic susceptibility; provides pathogen-level antibiogram context for antimicrobial selection
19941479	2010	Review	Curr Med Chem	Review of neglected bacterial diseases including trachoma; rifampin-containing regimens discussed in the context of Mycobacterium ulcerans and Chlamydia co-targeting strategies

Philippines Market Information

Rifampicin is currently not registered with the Philippine FDA. No marketing authorization records are available for any dosage form or brand in the Philippines. A de novo registration process would be required before any indication — original or repurposed — can be pursued through local regulatory channels.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for rifampicin in conjunctivitis sits at L3 — anchored primarily in 1970s non-randomized trials and case reports, with no prospective controlled clinical trials registered to date. While the mechanistic basis is scientifically credible and early studies support ocular use (particularly against Chlamydia-driven trachoma), the evidence base does not yet meet the threshold for a formal repurposing development program, and the risk of inducing resistance with monotherapy is a practical barrier.

To proceed, the following is needed:

Define the target conjunctivitis subtype: trachoma (C. trachomatis), bacterial (S. aureus, H. influenzae), or meningococcal — each has a distinct development pathway and regulatory precedent
Obtain rifampicin package insert data for Philippines-relevant safety review (warnings, contraindications, drug interactions), currently unavailable
Confirm topical ophthalmic formulation feasibility, including 1% rifampicin ointment or eye drop manufacturability in the Philippines
Assess resistance emergence risk through in vitro susceptibility profiling of locally circulating conjunctival pathogens
Design a prospective Phase 2 RCT in a well-defined conjunctivitis population before advancing further

Note on higher-priority indications in this Evidence Pack:

Two other predicted indications in this report carry stronger evidence and may warrant prioritization over conjunctivitis:

HIV/TB Co-infection (Rank 5, Evidence Level L1): Multiple completed Phase 3 trials (including NCT00001033 and NCT03851588) confirm the efficacy of rifampicin-based TB therapy in HIV-infected patients. The primary management challenge is potent CYP3A4/P-gp induction causing reduced ART exposure — manageable with dolutegravir 50 mg BID or efavirenz dose adjustment. Decision: Proceed with Guardrails.
Hidradenitis Suppurativa / Acne Inversa (Rank 3, Evidence Level L2): The clindamycin + rifampicin combination for 10–12 weeks is already incorporated into European S1/S2k guidelines and North American HS Foundation recommendations as a first-line systemic antibiotic option. This represents the most immediately actionable and guideline-supported repurposing opportunity in this pack. Decision: Proceed with Guardrails.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.